Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US based biopharmaceutical company, MiRagen Therapeutics, has presented positive data from a preclinical study which showed that microRNA-15 (miR-15) is upregulated to ischemic cardiac injury.
Subscribe to our email newsletter
The study also confirmed that inhibition of miR-15 can save cardiomyocytes from death during myocardial infarction.
MiRagen Therapeutics president and CEO William S Marshall said that the data indicates that antimiR-15 family therapy may induce a protective effect in response to ischemic cardiac injury by reducing infarct size and cardiac remodeling and by enhancing cardiac function.
"Combined with our findings showing that antimiR-15 therapy may also stimulate cardiomyocyte regeneration, these results suggest that inhibition of the miR-15 family represents a compelling dual mechanism approach to disease treatment in an area of significant unmet medical need," Marshall added.
The previous study also proved that inhibition of miR-15 could stimulate cardiomyogenesis.